Incyte (INCY)

• Market cap: $13.3B
• 1 day: 2.65%
• 5 days: -0.68%
• 1 month: -3.11%
• 3 months: 4.72%
• 6 months: 10.39%
• Year to date: 5.18%
• 1 year: 13.30%
• 5 years: -23.60%
• 10 years: -9.21%
• Sector: Industrials
• Industry: Commercial Physical & Biological Research

About: Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Employees: 2,524

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

40% more funds holding in top 10

Funds holding in top 10: 5 [Q2] → 7 (+2) [Q3]

16% more call options, than puts

Call options by funds: $49.9M | Put options by funds: $43M

5.83% more ownership

Funds ownership: 88.84% [Q2] → 94.67% (+5.83%) [Q3]

4% more first-time investments, than exits

New positions opened: 81 | Existing positions closed: 78

1% more funds holding

Funds holding: 569 [Q2] → 572 (+3) [Q3]

1% less capital invested

Capital invested by funds: $12.1B [Q2] → $11.9B (-$159M) [Q3]

35% less repeat investments, than reductions

Existing positions increased: 166 | Existing positions reduced: 255

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $52 24% downside
• Avg. target: $75 9% upside
• High target: $97 41% upside

10 analyst ratings

• positive: 3 30%
• neutral: 6 60%
• negative: 1 10%

Wells Fargo Derek Archila 53% 1-year accuracy 19 / 36 met price target	2% upside $70	Equal-Weight Maintained	19 Dec 2024
UBS Nicholas Holowko 13% 1-year accuracy 1 / 8 met price target	12% upside $77	Neutral Assumed	17 Dec 2024
RBC Capital Brian Abrahams 19% 1-year accuracy 15 / 79 met price target	8% upside $74	Sector Perform Maintained	19 Nov 2024
Citigroup David Lebowitz 45% 1-year accuracy 10 / 22 met price target	41% upside $97	Buy Maintained	30 Oct 2024
Morgan Stanley Vikram Purohit 43% 1-year accuracy 3 / 7 met price target	0% upside $69	Equal-Weight Maintained	30 Oct 2024